<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642690</url>
  </required_header>
  <id_info>
    <org_study_id>20-004618</org_study_id>
    <nct_id>NCT04642690</nct_id>
  </id_info>
  <brief_title>Nitrates and IL-8 in Barrett's Esophagus</brief_title>
  <official_title>The Association Between Nitrates, Nitrosylated Proteins, and Interleukin-8 in Barrett's Esophagus and Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if nitrates and IL-8 (which are found in food and&#xD;
      throughout the body regulating stomach acidity) play a role in Barrett's Esophagus and/or&#xD;
      Esophageal Adenocarcinoma severity and if screening for these biomarkers can help predict&#xD;
      patients that are more at risk for developing worsening disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nitrate Levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Nitrate levels in serum, saliva and tissue in patients with normal squamous epithelium, erosive esophagitis, non-dysplastic BE (NDBE), and BE with high-grade dysplasia (HGD) or EAC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum and Tissue Biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Levels of IL-8 in patients diagnosed BE dysplasia and EAC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers and disease progression</measure>
    <time_frame>Baseline</time_frame>
    <description>Level of IL-8 in serum and tissue in patients with NDBE that progressed to BE</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Group 1-NSE</arm_group_label>
    <description>Patients found to have grossly normal squamous epithelium during endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2-EEG</arm_group_label>
    <description>Patients found to have grossly apparent erosive esophagitis &gt;1cm with Los Angeles Classification A-D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3-NDBE Short</arm_group_label>
    <description>Patients with non-dysplastic Barrett's Esophagus (NDBE) &gt; 1cm (Short Segment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4-NDBE Long</arm_group_label>
    <description>Patients with non-dysplastic Barrett's Esophagus (NDBE) &gt; 1cm (Long Segment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>Barrett's Esophagus (BE) with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6-Esophagectomy</arm_group_label>
    <description>Patients undergoing resection of esophageal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group -7 Pilot and Feasibility</arm_group_label>
    <description>Patients undergoing EGD with NSE, NDBE, BE-HGD, or EAC for feasibility of analytical techniques</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult individuals scheduled for clinically indicated EGD procedure. Subjects with normal&#xD;
        squamous epithelium, erosive esophagitis, or varying degrees of Barrett's Esophagus may be&#xD;
        enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients undergoing a clinicallly-indicated Esophagogastroduoedoscopy (EGD).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comorbid inflammatory medical condition.&#xD;
&#xD;
          -  Use of antiinflammatory (aspirin and NSAIDs) or immunosuppressants over the past 1&#xD;
             week.&#xD;
&#xD;
          -  Use of nitrate containing medication in the past 1 week.&#xD;
&#xD;
          -  Consumption of nitrate rich foods in preceding 24 hours.&#xD;
&#xD;
          -  Known allergy to meat or nitrates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Katzka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>David A. Katzka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

